Hims & Hers Health (NYSE: HIMS) climbed more than 10% after Barclays raised its price target, highlighting strong momentum in the rapidly expanding GLP-1 weight-loss market. Robust revenue growth, higher guidance, and international expansion are reinforcing the company's long-term growth story.
Key Highlights
- Hims & Hers Health (NYSE: HIMS) surged more than 10%, outperforming both the healthcare sector and the broader market.
- Barclays raised its price target to $39 from $29 while maintaining an Overweight rating.
- Investors remain focused on the company's fast-growing GLP-1 weight-loss business.
- Q1 revenue reached $608 million, while management raised full-year 2026 guidance.
- The recently completed Eucalyptus acquisition expands the company's international footprint.
Why Hims & Hers Health (NYSE: HIMS) Stock Is Rallying
Hims & Hers Health (NYSE: HIMS) shares are sharply higher as investors continue to embrace the company's position as one of the fastest-growing digital healthcare platforms benefiting from the booming demand for GLP-1 weight-loss treatments.
The latest catalyst came from Barclays, which raised its price target on the stock to $39 from $29 while maintaining an Overweight rating. The firm cited accelerating GLP-1 demand, improving revenue visibility, and growing confidence in the company's long-term growth trajectory.
The upgrade adds to a wave of bullish sentiment that has increasingly centered on Hims & Hers Health's ability to capitalize on one of the most significant trends in healthcare: the rapid adoption of obesity and metabolic health treatments.
GLP-1 Momentum Remains the Core Growth Driver
The investment narrative surrounding Hims & Hers Health (NYSE: HIMS) has evolved considerably over the past year.
While the company initially built its business around telehealth services focused on areas such as dermatology, mental health, sexual wellness, and primary care, investor attention is now increasingly focused on its expanding presence in the GLP-1 market.
Demand for GLP-1 therapies has surged globally as medications originally developed for diabetes have demonstrated substantial effectiveness in weight management and metabolic health improvement.
The company has leveraged its digital-first platform to provide convenient access to treatment programs, allowing it to capture a growing share of this rapidly expanding market.
Barclays' target increase reflects expectations that GLP-1 demand could remain a meaningful growth catalyst for years to come.
Strong Revenue Growth Supports the Bull Case
The analyst upgrade follows another quarter of impressive financial performance.
Hims & Hers Health (NYSE: HIMS) reported first-quarter revenue of $608 million, continuing a trend of rapid top-line expansion that has consistently exceeded investor expectations.
The company also raised its fiscal 2026 revenue guidance to a range of $2.8 billion to $3.0 billion, signaling management's confidence in both customer acquisition trends and ongoing demand for its healthcare offerings.
For investors, guidance increases often carry more weight than historical results because they provide insight into future operating momentum.
The latest outlook suggests that management believes growth remains robust despite increasing competition across the telehealth and digital healthcare landscape.
International Expansion Creates Additional Opportunities
Another important catalyst supporting the stock is the recently completed acquisition of Eucalyptus.
The transaction expands Hims & Hers Health's (NYSE: HIMS) international presence and provides access to additional markets where digital healthcare adoption continues to accelerate.
International expansion has become increasingly important as investors seek evidence that the company can sustain high growth rates beyond its core U.S. operations.
The acquisition not only broadens geographic reach but also enhances the company's ability to scale its technology platform and healthcare delivery model globally.
As healthcare systems increasingly embrace virtual care solutions, international opportunities could become a meaningful contributor to future revenue growth.
Wall Street Increasingly Favors GLP-1 Exposure
The broader investment community is also becoming more constructive on companies positioned to benefit from GLP-1 adoption.
Recently, UBS identified GLP-1 beneficiaries as its highest-ranked global investment theme within its June REVS framework, reflecting expectations that the weight-loss and metabolic health market could continue expanding across multiple industries.
That theme extends beyond pharmaceutical manufacturers and increasingly includes healthcare service providers, telehealth platforms, diagnostics companies, and wellness-focused businesses.
Hims & Hers Health (NYSE: HIMS) is viewed as one of the more direct ways for investors to gain exposure to growing consumer demand for these treatments without investing directly in drug developers.
Retail Investors Remain Highly Bullish
Retail investor enthusiasm has also contributed to the stock's momentum.
Options activity remains heavily skewed toward call contracts, with approximately three-quarters of recent volume reflecting bullish positioning.
While options activity alone does not determine long-term performance, it highlights growing confidence among individual investors that the company's growth trajectory remains intact.
Combined with analyst upgrades and improving fundamentals, the sentiment backdrop remains supportive.
Outlook
Hims & Hers Health (NYSE: HIMS) continues to strengthen its position as one of the most prominent growth companies in digital healthcare. The combination of accelerating GLP-1 adoption, strong revenue growth, raised guidance, international expansion, and favorable analyst commentary has reinforced investor confidence in the company's long-term outlook.
The key question for investors is whether the company can sustain its current growth pace as competition intensifies and the GLP-1 market matures. For now, Wall Street appears increasingly convinced that Hims & Hers is well positioned to capture a meaningful share of one of healthcare's fastest-growing categories.
Investors will be watching GLP-1 subscriber growth, customer retention trends, international expansion progress, profitability metrics, and future guidance updates as the next major catalysts.






Please wait processing your request...